| ¿µ¹® | malignant tumor | ÇÑ±Û | ¾Ç¼ºÁ¾¾ç |
|---|---|---|---|
| ¼³¸í | Á¤»óÀûÀÎ Á¶Á÷ ¼¼Æ÷°¡ °¢Á¾ ¹°¸®Àû-ÈÇÐÀû-»ý¹°ÇÐÀûÀÎ ¹ß¾Ï ¹°ÁúÀÇ ÀÛ¿ë ¶Ç´Â ¿äÀο¡ ÀÇÇØ µ¹¿¬º¯À̸¦ ÀÏÀ¸ÄѼ Çü¼ºµÇ´Â Á¾¾ç. ¹«Á¦ÇÑÀÇ ¼¼Æ÷ºÐ¿·Î ¸Å¿ì ¿Õ¼ºÇÏ°Ô Áõ½ÄÇÏ¿© ÁÖÀ§Á¶Á÷À» ÆÄ±«-ħ½ÄÇÑ´Ù. ¶Ç ¾î¶² ÈÇй°ÁúÀ» ³»¾î ÁÖÀ§ÀÇ Á¶Á÷¼¼Æ÷¸¦ Ä§ÇØÇÒ »Ó¸¸ ¾Æ´Ï¶ó, Ç÷°ü ¹× ¸²ÇÁ°üÀ» µû¶ó ÀüÀÌÇÏ¿© Àü½ÅÀÇ Ä«ÄʽþƸ¦ÀÏÀ¸ÄÑ Á×À½À» ÃÊ·¡ÇÑ´Ù. »óÇǼºÀÎ °ÍÀ» ¾ÏÁ¾À̶ó Çϰí, ºñ»óÇǼºÀÎ °ÍÀ» À°Á¾À̶ó ÇÑ´Ù. |
||
| ¿µ¹® | benign tumor | ÇÑ±Û | ¾ç¼ºÁ¾¾ç |
|---|---|---|---|
| ¼³¸í | ¹ßÀ°¼Óµµ°¡ ¿Ï¸¸ÇÏ¿© ¼ºÀå¿¡ ÇѰ谡 ÀÖ°í, ÁÖÀ§¿ÍÀÇ °æ°è°¡ ¸íÈ®Çϸç, ´Ù¸¥ Á¶Á÷À¸·Î ÆÛÁöÁö ¾ÊÀ¸¸ç, ħÀ±À̳ª ÀüÀ̸¦ ÀÏÀ¸Å°Áö ¾Æ´ÏÇÏ´Â Á¾¾ç. ¼¶À¯Á¾À̳ª Áö¹æÁ¾ µûÀ§°¡ ÀüÇüÀûÀÎ ¿¹ÀÌ´Ù. ¾ç¼ºÁ¾¾çÀº Á¾¾çÀÌ Á¸ÀçÇÑ´Ù°í ÇØµµ 1Â÷ÀûÀ¸·Î ¼÷ÁÖÀÇ »ý¸íÀ» À§ÇùÇÏ´Â ÀÏÀº ¾ø´Ù. ¾ç¼ºÁ¾¾çÀÇ ¹ßÀ°Çü½ÄÀº ÁÖÀ§ÀÇ Á¶Á÷°£¿¡ ¿Õ·¡ÇÏ´Â ÀÏÀÌ ¾øÀÌ ÁÖÀ§ÀÇ Á¶Á÷À» ¹Ð¾î³»¸ç Áõ½ÄÇÑ´Ù. ¹ßÀ°¼Óµµ´Â ¿Ï¸¸Çϸç ÀüÀÌÇϰųª ÀýÁ¦ ÈÄ Àç¹ßÇÏ´Â ÀÏÀÌ ±ØÈ÷ µå¹°´Ù. Á¾¾ç¼ººÐÀº º¯ÀÌüÀ̱ä ÇÏÁö¸¸ ¼º¼÷ÇÑ Á¤»ó¼¼Æ÷¿Í °ÅÀÇ ´Ù¸¥ °ÍÀÌ ¾ø´Ù. Àü½Å¿¡ ´ëÇÑ ¿µÇâÀº ¾Ç¼ºÁ¾¾çÀÇ °æ¿ì ¾î´À Á¤µµ ¹ßÀ°ÇßÀ» ¶§ Àü½ÅÀÇ ¿µ¾ç»óŰ¡ ¼Õ»óµÇ¾î Ä«Äʽþư¡ µÇÁö¸¸ ¾ç¼ºÁ¾¾çÀÇ °æ¿ì ÀÌ·± ÀÏÀº °ÅÀÇ ¾ø´Ù. ¾ç¼ºÁ¾¾ç°ú ¾Ç¼ºÁ¾¾çÀÇ ¼º»óÀÇ Â÷ÀÌ¿¡ ¾ö¹ÐÇÑ °æ°è´Â ¾ø°í, °æ°è°æº¯À¸·Î º¸ÀÌ´Â Á¾¾çµµ ÀÖ´Ù. |
||
| ¿µ¹® | Wilms' tumor | ÇÑ±Û | Àª¸§ÁîÁ¾¾ç |
|---|---|---|---|
| ¼³¸í | ÄáÆÏ¿¡¼ ¹ß»ýÇÏ´Â ¾Ç¼ºÁ¾¾çÀ¸·Î ¼Ò¾Æ¿¡¼ ÀÚÁÖ ¹ß»ýÇÑ´Ù. ÈçÈ÷ ¼Ò¾Æ¿¡¼ º¹ºÎ³»Á¾¾çÀ» ¹ß°ß½Ã Áß¾Ó¼±À» ³Ñ¾î¼¸é ½Å°æ¸ð¼¼Æ÷Á¾À̰í, Áß¾Ó¼±À» ³ÑÁö ¾ÊÀ¸¸é Àª¸§ÁîÁ¾¾çÀ» ÀǽÉÇÒ ¸¸Å Áß¿äÇϰí ÈçÇÑ Á¾¾çÀÌ´Ù. ´ë°³ Áõ»óÀº ¾ø´Â ÆíÀ̸ç, ÁÖ·Î ¾Æ±âÀÇ ¸ñ¿åÀ» ½ÃÄÑÁÖ´Ù°¡ ¿ì¿¬È÷ ¹ß°ßµÈ º¹ºÎ³»Á¾±« ¶§¹®¿¡ º´¿øÀ» ã°Ô µÈ´Ù. Áø´Ü½Ã ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µÀ¸·Î ÁÖÀ§ÀÇ ÀüÀ̰¡ ¾ø´ÂÁö¸¦ È®ÀÎÇØ¾ß Çϸç, ÀüÀ̰¡ ¾øÀ¸¸é Ç×¾ÏÈÇпä¹ý, ¹æ»ç¼±Ä¡·á¿ä¹ý, ±×¸®°í ¼ö¼ú¿ä¹ýÀÇ º´ÇÕ¿ä¹ý¿¡ ÀÇÇÑ Ä¡·áÈ¿°ú°¡ ³ô´Ù. |
||
| ¿µ¹® | mucinous tumor | ÇÑ±Û | Á¡¾×Á¾¾ç |
|---|---|---|---|
| ¼³¸í | Á¡¾×À¸·Î ±¸¼ºµÈ Á¾¾çÀ» ¸»Çϴµ¥ ÁÖ·Î ¿©¼ºÀÇ ³¼Ò¿¡¼ ¹ß»ýÇÏ´Â ³¶¼º(¹°ÁָӴϰ°Àº Á¾¾çÀ» ¸»ÇÔ) Á¾¾ç¿¡¼ ¸¹ÀÌ º¼ ¼ö ÀÖ´Ù. |
||
| ¿µ¹® | tumor | ÇÑ±Û | Á¾¾ç |
|---|---|---|---|
| ¼³¸í | Á¶ÀýÇÒ ¼ö ¾øÀÌ °è¼Ó ÁøÇàµÇ´Â ¼¼Æ÷ºÐ¿¿¡ ÀÇÇÑ Á¶Á÷ÀÇ »õ·Î¿î Áõ½Ä ¹× Áõ´ë. ½Å»ý¹°. (1) ºÐ·ù A. ħÀ±°ú ÀüÀÌÀÇ À¯¹«¿¡ µû¶ó i)¾ç¼ºÁ¾¾ç: ħÀ±°ú ÀüÀ̰¡ ¾ø°í ¿ªÇü¼ºÀÌ ³·Àº ¼¼Æ÷·Î ±¸¼ºµÊ. ´ë°³ Ä¡·á¿¡ ¹ÝÀÀÀÌ ³ô°í, »ý¸í¿¡ Å©°Ô ÁöÀåÀÌ ¾øÀ¸¸ç, Àç¹ßÇÏ´Â °æ¿ìµµ Àû´Ù. Áõ»óÀº ´ÜÁö ÁÖÀ§Á¶Á÷¿¡ ´ëÇÑ ¾Ð¹ÚÁ¤µµÀÌ´Ù. ii)¾Ç¼ºÁ¾¾ç: ħÀ±°ú ÀüÀ̰¡ ÀÖ°í Åðȵµ°¡ ³ôÀº ¼¼Æ÷·Î ±¸¼ºµÊ. ±â¿ø¼¼Æ÷°¡ »óÇÇÁ¶Á÷ÀÏ °æ¿ì ¾ÏÁ¾, ºñ»óÇǼºÀÏ °æ¿ì À°Á¾À¸·Î ³ª´©±âµµ ÇÑ´Ù. Ä¡·á¿¡ Àß ¹ÝÀÀÇÏÁö ¾Ê°í, Àç¹ßÀ» Àß Çϸç, »ýÁ¸À²ÀÌ ³·´Ù. ÈçÈ÷ ¸»ÇÏ´Â ¡°¾Ï¡±À» ÀǹÌÇÑ´Ù. B. Á¶Á÷ÇÐÀû Ư¡¿¡ µû¶ó »ùÁ¾, Áö¹æÁ¾, ±ÙÁ¾ µîÀ¸·Î ³ª´©±âµµ ÇÑ´Ù. (2) º´¸®Á¶Á÷ÇÐÀû Ư¡ A. À°¾ÈÀû ¼Ò°ß µ¢¾î¸®¸¦ Çü¼ºÇϱ⵵ Çϰí Á¤»óÁ¶Á÷¿¡ ½º¸çµéµíÀÌ ÆÇ»ó±¸Á¶¸¦ ÀÌ·ç±âµµ ÇÏ´Â µî ´Ù¾çÇÑ ÇüŸ¦ º¸ÀδÙ. ¾ç¼ºÀÇ °æ¿ì ÇǸ·À» °¡Áø °æ¿ì°¡ ¸¹°í ¾Ç¼ºÀÇ °æ¿ì ¾ø´Â °æ¿ì°¡ ¸¹´Ù. À°¾È¼Ò°ß¿¡ µû¶ó ´ÙÀ½°ú °°ÀÌ ³ª´«´Ù. ³¶¼º, À¶±â¼º, ±«»ç¼º, Æú¸³¸ð¾ç, ±Ë¾çÇü µîÀÌ ÀÖ´Ù. ¶Ç´Â ¼¼Æ÷ÀÇ Å©±â¿Í ¸ð¾çÀÌ ºñÁ¤»óÀûÀÎ ÇüÅ·Πº¯ÈÇÑ´Ù. ÇÙÀÇ ±Ø¼ºÀÌ »ç¶óÁö°í ÇÙÀÇ ¿°»ö¼ºÀÌ Â£¾îÁø´Ù. ¼¼Æ÷ÁúÀÇ ¿°»ö¼ºµµ º¯ÈÇÏ¸ç ¼¼Æ÷µé°£ÀÇ ¼¼Æ÷ÁֱⰡ ¸Å¿ì ´Ù¾çÇØÁ® ¸¹Àº ¼¼Æ÷ºÐ¿À» º¸ÀδÙ. ÀÌ·¯ÇÑ ÀÏ·ÃÀÇ º¯È¸¦ ¿ªÇü¼ºÀ̶ó ÇÑ´Ù. ¿ªÇü¼ºÀÇ Á¤µµ¿¡ µû¶ó Á¶Á÷ÇÐÀû µî±ÞÀ» ³ª´«´Ù. ¶ÇÇÑ °¢ Á¾¾ç¿¡ µû¶ó °¢±â ´Ù¸¥ º´¸®Á¶Á÷ÇÐÀû ¸íĪÀ» ºÙÀδÙ. |
||
| CT | calcitonin; calf testis; cardiac tamponade; cardiothoracic [ratio]; carotid tracing; carpal tunnel; ... |
|---|---|
| TNM | primary tumor, regional nodes, metastasis [tumor staging]; thyroid node metastases; tumor node metas... |
| Gm | an allotype marker on the heavy chains of immunoglobins |
| mar | margin; marker [chromosome] |
| mar(X) | marker X [chromosome] |
| hypoxanthine-guanine phosphoribosyl tranferase marker | The gene which codes for the enzyme hypoxanthine-guanine phosphoribosyl transferase. It is a selectable marker because cells which have a defective version of this gene are resistant to poisoning by toxic purine derivatives which result from the metabolic pathway that the HGPRT enzyme catalyses. (The purine derivatives are toxic because they incorporate into DNA as a result of the HGPRT enzyme's actions). Because the defective gene cannot produce the enzyme, no toxic purine derivatives are produced, the gene can therefore be selected for. (09 Oct 1997) |
|---|---|
| surrogate marker | <biology> A laboratory measurement of biological activity within the body that indirectly indicates the effect of treatment on disease state. CD4 cell counts and viral load are examples of surrogate markers in HIV infection. (19 Jan 1998) |
| oncofetal marker | A tumour marker produced by tumour tissue and by foetal tissue of the same type as the tumour, but not by normal adult tissue from which the tumour arises. (05 Mar 2000) |
| time marker | An instrument that marks the time, usually in seconds or fractions of seconds, on a kymograph record in physiologic experiments. (05 Mar 2000) |
| tumour marker | <investigation, oncology> A substance in the body that usually indicates the presence of cancer. These markers are usually specific to certain types of cancer and are usually found in the blood or other tissue samples. Examples are alphafetoprotein (AFP), human chorionic gonadotropin, and lactate dehydrogenase (LDH). They may be indicators of tumour stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids. (18 Jul 2002) |
| linkage marker | A locus at which there is a high probability of heterozygotes (indispensible state for linkage analysis), but in itself perhaps of no clinical interest. See: marker locus. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|